These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32440826)

  • 1. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan.
    Sullivan E; Kershaw J; Blackburn S; Mahajan P; Boklage SH
    Rheumatol Ther; 2020 Sep; 7(3):517-535. PubMed ID: 32440826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.
    Sullivan E; Kershaw J; Blackburn S; Choi J; Curtis JR; Boklage S
    Rheumatol Ther; 2020 Jun; 7(2):383-400. PubMed ID: 32318979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
    Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
    Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cycling of tumor necrosis factor inhibitors
    Migliore A; Pompilio G; Integlia D; Zhuo J; Alemao E
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211002682. PubMed ID: 33854570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
    Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor.
    Caporali R; Kadakia A; Howell O; Patel J; Milligan J; Strengholt S; Barlow S; Taylor PC
    Adv Ther; 2024 Sep; 41(9):3706-3721. PubMed ID: 39110310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
    Youssef P; Marcal B; Button P; Truman M; Bird P; Griffiths H; Roberts L; Tymms K; Littlejohn G
    J Rheumatol; 2020 Aug; 47(8):1174-1181. PubMed ID: 31787605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
    Bonafede MMK; McMorrow D; Proudfoot C; Shinde S; Kuznik A; Chen CI
    Am Health Drug Benefits; 2018 Jun; 11(4):192-202. PubMed ID: 30464787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
    Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
    Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.
    Bonafede MM; Curtis JR; McMorrow D; Mahajan P; Chen CI
    Clinicoecon Outcomes Res; 2016; 8():707-715. PubMed ID: 27980429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.